详情
Leptin Antagonist Triple Mutant Human Recombinant, Pegylated
目录号 | AP3575 |
---|---|
Physical Appearance | White lyophilized (freeze-dried) powder. |
Formulation | The protein was lyophilized from a concentrated (0.65mg/ml) solution with 0.003mM NaHCO3. |
Protein biological activity | Capable of inhibiting leptin-induced proliferation of BAF/3 cells stably transfected with the long form of human leptin receptor. Its in vitro activity is 6-8 fold lower than the non-pegylated antagonist but in vivo it has profound weight gain effect (as compared to the non-pegylated antagonist), resulting mainly from increased food intake. Its in vivo activity compared to that of PEG-MLA is 9-27 fold higher. |
Purity | Greater than 98.0% as determined by: (a) Gel filtration analysis. (b) Analysis by SDS-PAGE. |
Solubility | It is recommended to reconstitute the lyophilized Leptin Antagonist Triple Mutant pegylated Human Recombinant in sterile 0.4% NaHCO3 adjusted to pH 8-9, not less than 100µg/ml, which can then be further diluted to other aqueous solutions. |
Stability | Lyophilized PEG-SHLA although stable at room temperature for several weeks, should be stored desiccated below - 20C. Upon reconstitution at > 0.1 mg/ml and up to 2 mg/ml of PEG-SHLA and filter sterilization mLEP mutant can be stored at 4C or even room temperature for several weeks making it suitable for long term infusion studies using osmotic pumps. At lower concentration addition of a carrier protein (0.1% HSA or BSA) is suggested. Please prevent freeze-thaw cycles. |
Source | Escherichia coli. |
Transportation method | Shipped at Room temp |
产品资料
产品标签
Product Questions
Product Questions
No Questions